Santen Announces Sydnexis European Pivotal Data
Santen announced Sydnexis SYD-101 Phase III clinical data and is expecting European approval in early 2025 for the treatment of pediatric progressive myopia. Santen licensed SYD-101 for Europe, Middle East, and Africa from Sydnexis. Sydnexis is also seeking approval for the United States. Pediatric progressive myopia impacts ~28 million patients in the United States alone. Left untreated leads to immediate loss of QOL for patients and increases vision risks later in life: cataract (5x), glaucoma (14x), retinal detachment (44x), & myopic maculopathy (348x).